SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Henry Niman who wrote (15420)2/19/1998 11:39:00 PM
From: Machaon  Respond to of 32384
 
Henry, there is a lot to like about LGND's chances. But what impresses me is the number of business partners that they have. It is really significant. These big drugsters do not throw around $millions on just hype, without any research or understanding of possible profits. In other words: "Don't take Henry's word for it, take LLY's, ... etc, word for it".

I yearn for the earlier days of this thread when we joked about eating peanut butter, as we sat with our losses and waited for the "Breakout". There were pros and cons, but mostly in a friendly atmosphere. It's getting so annoying that I want LGND to hit $100 per share, not just for the money, but just to get rid of those who thrive on dissension.

<< Actually, my "spin" was a quick read as I was heading out the door >>

Henry, we are going to get a special prosecutor to probe into whether or not you really headed out the door!! <g>

<< peer influence is rather strong >>

Good point. It reminds me of middle school kids.

You spend a lot of your personal time to publish a lot of material for all to read. Unfortunately, you also are subject to abuse for doing this and for giving your opinion about LGND.

I, for one, who has invested in LGND, would really welcome substantive posts saying why I shouldn't invest in LGND.

Oh, by the way, I don't remember. Did I ever say that I would like to see LGND at $100, but not for the money???

Regards, Bob